Global Anti-Cancer MAbS Market Segments 2024, Forecast To 2033
5 Mar, 2024
The anti-cancer monoclonal antibodies (mAbs) market, growing rapidly, will increase from $59.98 billion in 2023 to $66.1 billion in 2024, with a CAGR of 10.2%. Historic growth is attributed to increasing cancer incidence rates, growing understanding of cancer biology, a rise in personalized medicine approaches, increased investment in research and development, and growing patient awareness and demand. The forecast period anticipates strong growth to $95.99 billion in 2028 (CAGR of 9.8%), driven by advancements in immunotherapy, increasing adoption of combination therapies, the emergence of next-generation mAbs, global efforts to address the cancer burden, and the expansion of patient access programs. Key trends include innovations in drug delivery technologies, the integration of artificial intelligence in drug discovery, collaborations and partnerships in the pharma industry, advancements in biotechnology, and CAR-T cell therapies.
Global Anti-Cancer MAbS Market Key Driver
The increasing prevalence of cancer globally propels the growth of the anticancer MABs market. With an estimated 1.9 million new cancer cases worldwide, the demand for anticancer monoclonal antibodies (mAbs) is on the rise. These antibodies are designed to target and destroy cancer cells, contributing to treatment strategies. The escalating prevalence of cancer underscores the crucial role of anticancer MABs in addressing this chronic disease.
Get A Free Sample Of The Global Anti-Cancer MAbS Market ReportGlobal Anti-Cancer MAbS Market Segments
The anti-cancer mabs market covered in this report is segmented –
1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types
2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications
3) By End User: Hospitals, Research Institutes, Other End Users
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the anti-cancer MAbS market in 2023. Asia Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mabs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Anti-Cancer MAbS Industry Players
Amgen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Johnson & Johnson; Novartis AG; Merck & Co. Inc.; Spectrum Pharmaceuticals Inc.; AstraZeneca plc.; Pfizer Inc.; Gilead Sciences Inc.; Bayer HealthCare; ImmunoGen Inc.; Genentech Inc.; AbbVie Inc.; Takeda Pharmaceuticals; Seattle Genetics; Regeneron Pharmaceuticals; Celgene; Ipsen; Daiichi Sankyo; Kite Pharma; ADC Therapeutics; MacroGenics Inc.; BioXcel Therapeutics; Zymeworks Inc.; Exelixis Inc.; Blueprint Medicines; Erytech Pharma; Oncopeptides AB
Get The Full Global Anti-Cancer MAbS Market Report
AIOps Anti-Cancer MAbS Market Overview
Anticancer monoclonal antibodies (mAbs) are the antibodies used for monoclonal antibody therapy to target and destroy cancer cells. These mAbs are intended to bind to specific proteins or chemicals located on the surface of cancer cells, preventing cancer growth, and spread.
Anti-Cancer MAbS Global Market Report 2023 provides data on the global anti-cancer mabs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The anti-cancer mabs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.